

## Status of CTR implementation preparation in Finland


Dr. Pirjo Inki  
Head of Clinical Trials  
Fimea

1


### Safety

- Fimea has started Safety reporting MS-roles in 2019
- Fimea has started to use VHP DSUR AR:s in assessment of nationally submitted DSUR:s
- Sufficient competence expected to be gained through VHP participation by time of CTR implementation

2




3



4

## fimea National IT system

- Work in progress: preparation for fully electronic submissions (estimated: Jan/2020) pre- CTR & transition period
- Electronic archiving
- IT Solutions for communication systems with Ethics committee not yet solved



5

## fimea

### Fees

- Fees will be decided by Ministry of Social Affairs and Health, Ethics committee and Fimea
- Work-time calculations in place in Fimea for VHP processes (in different roles + amendments, safety assessments etc)

6

## Pilot projects

- SOP for National pilot (Fimea+ Tukija) was agreed -> joint assessment has not started due to Tukija's resource issues
- Fimea started a pilot as own project Oct 2019 (implementation of CTR templates and timelines): voluntary for sponsors to participate; so far 2 applications have been piloted
- Fimea has participated in VHP:s since 2015
  - Q1-Q3/2019 New VHP applications: 4 Ref- NCA roles, 13 P-NCA roles = 17 new VHPs
  - Q1-Q3/2019 VHP Amendments: 9 Ref-NCA roles, 71 P-NCA roles = 80 VHP Am:s
- More experience needed

7

## National law

- National law expected to be submitted for approval by the parliament by end of 2019
- Some sections are intended to be applied already in 1/2020
  - These sections concern implementation of the GDPR in both clinical trials and other medical research
- Object of national legislation is to create flexible and research friendly environment
- Accepted languages for applications: Finnish, Swedish and English
  - Materials for the subject must be in Finnish/Swedish

8

## Ethics committee's structure

- Outlined in National Law
- Resources for implementation and practice in VHP+ pending
- There will be one national ethics committee to assess all clinical trials, operating by the National Supervisory Authority for Welfare and Health
- Committee will be appointed for 4 years at a time
- There must be experts in clinical trials, medicine, statistics, ethics and law (plus one layperson) in the Committee
- The Committee must include a chairman + at least 30 other members (pool of experts)
  - The Committee can also use permanent or temporary experts from outside the Committee
- In addition to assessing clinical trials applications, the Committee has other tasks defined in legislation, such as acting as an expert in ethical questions and taking part in international cooperation

## NCA-EC organization

- Assessment of an application will be independent in NCA and EC but the two will collaborate in order to ensure high quality assessment and fluency of the process
  - The EC can express its' views for the NCA concerning validation of an application
  - The EC can take part in finalizing part I of the assessment report
  - The EC and NCA can advise each other in questions concerning an application or common scientific, ethical, legal or practical issues
  - Fimea can express views/comment to part II
- The NCA must take into account the views of the EC



Lääkealan turvallisuus- ja kehittämiskeskus |

| Kliinisten tutkimusten arviointiprosessi draft 5.2017

| |